Trial Profile
A long-term study of the safety of rituxan in patients with rheumatoid arthritis after an inadequate response to previous Anti-TNF [tumour necrosis factor] therapy (SUNSTONE).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- Acronyms SUNSTONE
- Sponsors Genentech
- 26 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 05 Dec 2012 Planned End Date added 1 Dec 2013 as reported by ClinicalTrials.gov record.
- 12 Nov 2010 Additional lead investigator identified as reported by ClinicalTrials.gov.